echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Circulation Research | Li Hongliang's team from Wuhan University publishes a review on non-alcoholic fatty liver disease

    Circulation Research | Li Hongliang's team from Wuhan University publishes a review on non-alcoholic fatty liver disease

    • Last Update: 2021-06-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Editor’s note iNature is China’s largest academic official account.
    It is jointly created by the doctoral team of Tsinghua University, Harvard University, Chinese Academy of Sciences and other units.
    The iNature Talent Official Account is now launched, focusing on talent recruitment, academic progress, scientific research information, interested parties can Long press or scan the QR code below to follow us.

    iNature arrhythmia and the resulting sudden cardiac death are serious cardiovascular complications that continue to bring a heavy burden to patients and society.

    A piece of emerging evidence suggests that non-alcoholic fatty liver disease (NAFLD) is closely related to the risk of arrhythmia, independent of other traditional cardiometabolic comorbidities.

    Although most studies have focused on the relationship between NAFLD and atrial fibrillation, there are also reports that it is related to ventricular arrhythmias and cardiac conduction defects.

    Mechanism studies have shown that many pathophysiological changes related to NAFLD may trigger structural, electrical and autonomic remodeling of the heart, leading to cardiac arrhythmia.

    NAFLD is now the most common liver and metabolic disease in the world.

    However, as a new risk factor for arrhythmia, the increase in the prevalence of NAFLD has received little attention.

    On May 28, 2021, Li Hongliang of Wuhan University and Cai Jingjing of Central South University jointly published a long review titled "Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia" online in Circulation Research (IF=14.
    462).
    The previous article systematically discussed the mechanism and clinical evidence of the occurrence and development of arrhythmia caused by non-alcoholic fatty liver (NAFLD), and proposed that NAFLD is an important risk factor that promotes arrhythmia.
    This theory will help prevent and control the clinical risk of arrhythmia.
    The formulation of treatment strategies.

    In the past five years, Professor Li Hongliang has been invited to publish more than 20 reviews of NAFLD and related fields in a series of top international journals, including Physiological Reviews, Annual Review of Pathology, Advance Science, Circulation Research, etc.

    Li Hongliang’s team analyzed the epidemiological characteristics and development trends of non-alcoholic fatty liver disease (NAFLD) in China in the past 20 years, and put forward NAFLD-related policy guidance and research gaps that need to be resolved; based on system biology screening and in-depth pathology and molecular In biological research, Li Hongliang’s team discovered and confirmed a series of new therapeutic targets for non-alcoholic steatohepatitis; innate immune signal transduction also regulates the development of cardiovascular and metabolic diseases, especially non-alcoholic fatty liver disease and cardiovascular disease.

    [1] On January 1, 2019, Li Hongliang's team from Wuhan University published a review article titled "Innate Immune Signaling and Its Role in Metabolic and Cardiovascular Diseases" in Physiological Reviews (IF=25.
    584).
    The review summarized innate immune signals The research progress of transduction and the regulatory role of innate immunity in cardiometabolic diseases.

    Therefore, further study of the innate immune signals of the cardiometabolic system may help to discover new therapeutic strategies to control the occurrence and development of cardiometabolic disorders.

    [2] On January 24, 2019, Li Hongliang and Cai Jingjing of Wuhan University jointly published an online review article entitled "Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases" in Annual Review of Pathology (IF=16.
    754).
    The review In the context of non-alcoholic fatty liver disease (represented by metabolic diseases and cardiovascular diseases), how the innate immune system interacts with metabolic disorders to trigger the pathogenesis of immune dependence and immune independence.

    [3] On February 20, 2019, Li Hongliang and others from Wuhan University published an online review titled "Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases" in Advance Science (IF=15.
    840).
    The review comprehensively summarized The current understanding of NAFLD provides important summaries in five areas including epidemiology, diagnosis, animal models, pathogenesis and treatment, and emphasizes important breakthroughs in clinical trials and the most promising drugs and emerging therapeutic targets.
    Hope to bring new insights into the characterization of NAFLD.

    [4] On April 7, 2021, Zhe Zhigang and Li Hongliang of Wuhan University jointly published an online review article entitled "Therapeutic Potential of G Protein-Coupled Receptors against Nonalcoholic Steatohepatitis" in Hepatology (IF=14.
    673).
    The review analyzed The latest report of GPCR in NASH, G protein-coupled receptor (GPCR) represents the largest targetable drug in the human genome, which strongly regulates pathophysiological events, and discusses the trend of using GPCR as a therapeutic target for NASH.

    [5] On February 27, 2020, the Li Hongliang team of Wuhan University published an online review article entitled "Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases" in Circulation Research (IF=14.
    462).
    The review systematically analyzed and summarized the support for NAFLD As the clinical evidence of cardiovascular disease epidemic risk factors, and discussed the main mechanism of accelerating the progression of cardiovascular disease in NAFLD.

    Finally, the review discussed the potential treatments of NAFLD and its potential impact on cardiovascular disease, and proposed that attention to NAFLD management has important clinical significance for the prevention of cardiovascular disease.

    [6] On October 6, 2019, Li Hongliang and Cai Jingjing of Wuhan University jointly published an online review article entitled "Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease" in the Cell sub-Journal Trends in Endocrinology & Metabolism (IF=11.
    643) This review summarizes emerging molecular targets involved in NAFLD lipid metabolism and innate immune signaling, with a focus on exploring their mechanism of action and clinical transformation potential.

    [7] On August 18, 2018, the Li Hongliang team of Wuhan University published a review titled "Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease" in Trends in Endocrinology & Metabolism (IF=11.
    643).
    The focus of the review is to emphasize New evidence for the role of innate immunity in NAFLD and the integration of different pathways that influence inflammation and metabolism in this liver pathogenesis spectrum.

    [8] On March 30, 2018, Li Hongliang's team from Wuhan University published a review titled "Progress and challenges in the prevention and control of nonalcoholicfatty liver disease" in Medicinal Research Reviews (IF=9.
    304).
    This review summarizes the disease Characteristics and prevalence, as well as the status of understanding of its mechanism and potential therapeutic targets.

    Arrhythmia is one of the most common clinical complications in patients with cardiovascular disease.
    Due to the high prevalence and high risk, it has become an important public health and medical problem.

    NAFLD is the most common liver and metabolic disease in the world.
    In 2018, the global prevalence rate was about 25% (that is, 1.
    7 billion people).
    The number of NAFLD patients even exceeded the sum of obese people (650 million) and diabetic people (400 million).
    .

    Studies have shown that NAFLD is closely related to the risk of arrhythmia, and many pathophysiological changes related to NAFLD can cause changes in the electrical remodeling of the heart, leading to arrhythmia.

    In the past ten years, many studies have confirmed that NAFLD is a multi-system disease, and NAFLD, as an important risk factor for a new arrhythmia, causes the prevalence of patients to continue to rise, but it has received little attention.

    More and more clinical studies have shown that NAFLD is associated with an increased risk of arrhythmias (such as atrial fibrillation and ventricular arrhythmia), but the current cardiovascular disease prevention and control guidelines do not list NAFLD as an important risk of cardiovascular disease The indicators are routinely screened and treated.

    Figure The underlying mechanism of non-alcoholic fatty liver (NAFLD) causing arrhythmia.
    This research review summarizes NAFLD and atrial fibrillation, ventricular arrhythmia, and cardiac conduction in the United States, Italy, China, South Korea, the United Kingdom, Germany, Finland and other countries and regions.
    Clinical epidemiological evidence related to cardiac autonomic nerve dysfunction and other clinical epidemiological evidence; at the same time, it clarified the potential mechanism of NAFLD and the occurrence and development of arrhythmia, and emphasized that NAFLD may be an independent risk factor for the development and development of arrhythmia.
    Clinical diagnosis and treatment of arrhythmia and cost management, raising public awareness and formulating public policy intervention measures are of great significance.

    Reference message: https://
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.